Recurrent Implantation Failure Management and Outcomes

Recurrent implantation failure (RIF) describes the inability to achieve a clinical pregnancy after multiple high-quality embryo transfers, typically following at least two or three unsuccessful in vitro fertilisation cycles. Its multifactorial aetiology encompasses embryonic factors, endometrial receptivity anomalies, uterine pathology, immunological dysregulation and genetic variants. A comprehensive evaluation includes imaging to exclude structural anomalies, histological or molecular assays of endometrial receptivity, immunoprofiling for cytokine imbalances or autoantibodies, microbiome assessment and genetic testing of both gametes and embryos. Management strategies are increasingly personalised, combining improved embryo selection through morphokinetics or pre-implantation genetic testing, tailored transfer protocols such as sequential embryo transfer, adjunctive therapies including intrauterine perfusion, luteal-phase human chorionic gonadotropin support and immunomodulatory interventions. Molecular biomarkers and immune‐cell signatures are under investigation to predict implantation potential and refine treatment selection. Overall, integration of diagnostic precision and targeted therapies has led to incremental gains in implantation and live birth rates, although the optimal combination of interventions remains under active study worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Recurrent Implantation Failure Management and Outcomes publication trend

The graph below shows the total number of articles in recurrent implantation failure management and outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Recurrent implantation failure (RIF): Failure to achieve pregnancy after multiple transfers of high-quality embryos in assisted reproduction.

Endometrial receptivity: The state of the uterine lining during the window of implantation, when molecular and cellular conditions permit embryo attachment.

Sequential embryo transfer: Transfer of embryos at two developmental stages (cleavage and blastocyst) within the same cycle to extend the implantation window.

Intrauterine perfusion: Administration of therapeutic agents or fluids into the uterine cavity to modulate endometrial factors prior to embryo transfer.

Weighted gene co-expression network analysis (WGCNA): A systems biology method for identifying clusters of co-expressed genes and their correlations with clinical traits.

Cytokine profile: The array and relative levels of signalling proteins secreted by immune cells, reflecting inflammatory or regulatory responses.

Th1/Th2 balance: The relative dominance of type 1 (cell-mediated) versus type 2 (humoral) T helper cell immune responses, influencing implantation success.

References

1. Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions. Reproductive Biology and Endocrinology (2018).
2. Alterations of Cytokine Profiles in Patients With Recurrent Implantation Failure. Frontiers in Endocrinology (2022).
3. Sequential embryo transfer combined with intrauterine perfusion improved pregnancy outcomes in patients with recurrent implantation failure. BMC Women's Health (2024).
4. Analysis of weighted gene co-expression networks and clinical validation identify hub genes and immune cell infiltration in the endometrial cells of patients with recurrent implantation failure. Frontiers in Genetics (2024).